Sign in
Enrolling by invitationPhase 4

ESCUDDO Long Term Follow Up

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Costa Rica1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Phase 4
People taking part
13,700 people, planned
Started
11 Aug 2026
Expected to end
15 Jan 2031
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
  • Recombinant Human Papillomavirus Nonavalent Vaccine
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • TRIAL PARTICIPANTS: Participation in ESCUDDO base study
  • TRIAL PARTICIPANTS: Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms
  • TRIAL PARTICIPANTS: A signed informed consent form for ESCUDDO LTFU
  • TRIAL PARTICIPANTS: Opportunity to complete three total study visits
  • LTFU SURVEY GROUP: We will match the current ages of ESCUDDO LTFU trial participants when they attend their 9.5-year study visit (21 to 26 years of age)

Who cannot take part

  • TRIAL PARTICIPANTS: Enrollment cannot occur beyond her 10 year study visit
  • LTFU SURVEY GROUP: They report they are pregnant
  • LTFU SURVEY GROUP: They report being vaccinated against HPV
  • LTFU SURVEY GROUP: The qualified healthcare personnel determining eligibility, in agreement with principal investigator, considers a reason that precludes participation; or
  • LTFU SURVEY GROUP: They do not have an identification document

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Human papillomavirus infection or human papillomavirus-related malignant neoplasm

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.

The 3 groups in the trial

  • Arm I (Gardasil, Tdap)Treatment being tested

    ONE DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.

    Treatment: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed and Recombinant Human Papillomavirus Nonavalent Vaccine

  • Arm II (2 Doses Gardasil)Existing treatment, for comparison

    TWO DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.

    Treatment: Recombinant Human Papillomavirus Nonavalent Vaccine

  • Arm III (epidemiologic survey)No study treatment, for comparison

    UNVACCINATED: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study. These women will be offered HPV vaccination (Gardasil9).

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")
Criteria questions
Built from NCT07706673, who can take part
Record updated
18 November 2026